Bionor Pharma issue stock option program for employees
Oslo 15.03.2013 - The Board of Directors in Bionor Pharma ASA has approved anew stock option program for 13 employees as part of an incentive program foremployees in Bionor Pharma.
The program issues 1,520,000 options and has three years vesting period. The
options are exercisable at a price of NOK 2.48 per share, equivalent to the
closing share price on 15 March 2013. The options vest by 1/3 on 1 June
2014, 1/3 on 1 June 2015 and remaining 1/3 on 1 June 2016.
The share options can be issued according to the power of attorney from the
General Meeting on 11 May 2012 to issue up to 10 million options to
management as part of the incentive system. The total number of outstanding
share options in Bionor Pharma is now 8.62 million.
The following primary insiders have been granted options in this program:
Hilde Aalling Syvertsen (Director Communications & Corporate Affairs) has
received 200.000 options. Following the receipt of the options Hilde Aalling
Syvertsen holds 758.000 shares and 200.000 options in Bionor Pharma ASA.
Mats Ökvist (Director Technology & Patent) has received 200.000 options.
Following the receipt of the options Mats Ökvist holds 200.000 options in Bionor
Arnt-Ove Hovden (Director of Viral Immunology) has received 200.000 options.
Following the receipt of the options Arnt-Ove Hovden holds 200.000 options in
Bionor Pharma ASA.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Bionor Pharma ASA, Oslo: +47 23 01 09 60
Hilde Aalling Syvertsen, Director Communications & Corporate Affairs